New Pathways in Advanced SM

Objectives: - Exploring the complexities in testing for Advanced SM - Defining treatment objectives in Advanced SM with a focus on evidence-based and patient-centered approaches - Understanding the disease pathology and prognostics of Chronic Myelomonocytic Leukaemia (CMML), a commonly associated hematologic neoplasm in Advanced SM - Exploring the current treatment landscape of Advanced SM in the UK, and addressing regional advancements and challenges in Advanced SM care This event has been CPD certified and is open to healthcare professionals with an interest in Advanced Systemic Mastocytosis (SM).

You are invited to join Blueprint Medicines, Dr Deepti Radia, and a panel of experts to enhance your understanding of diagnosing and treating Advanced Systemic Mastocytosis (SM). This event has been CPD-certified and is open to healthcare professionals with an interest in Advanced Systemic Mastocytosis (SM).

Meeting agenda
12:00–13:30 Arrival and registration (Buffet lunch provided)

13:30–13:35 Introduction

13:35–13:40 Patient spotlight video

13:40–13:55 What is Advanced SM?

13:55–14:30 Suspecting Advanced SM: from histopathology to molecular profiling

14:30–14:45 Coffee break

14:45–15:20 Multidisciplinary approaches

15:20–15:50 CMML — pathology and prognostics

15:50–16:10 Current advances in the management of Advanced SM

16:10–16:15 Summary and closing remarks

Follow the link to register: www.impacct-meetings.com/newpathwaysinadvancedsm